Go to main content
Tricals - The highway towards a cure
ALS and other Motor Neurone Diseases Centre

CHU Nice

France - Nice
Go to:
Specialists in this centreContact and locationCurrent trials in this centre

The ALS and other Motor Neurone Diseases Centre at Nice University Hospital, located in Pasteur 2 Hospital, has been a recognized reference centre since 2003. It offers comprehensive multidisciplinary care for ALS patients, provides support for their families, and actively engages in clinical research to advance treatment of ALS.

The ALS and other Motor Neurone Diseases Centre, part of the Neurology Department at Nice University Hospital, is dedicated to the care of patients with ALS and related motor neurone diseases. The Centre offers specialized inpatient and outpatient services, supported by a dedicated team of professionals. Each year, it provides multidisciplinary care to over 200 patients, including 60 newly diagnosed ALS cases. In addition to patient care, the centre is actively involved in international clinical research, participating in clinical trials and academic studies. A key focus of their research is on brain-computer interfaces and innovative technologies aimed at compensating for physical disabilities.

Specialists in this centre

Marie-Helene Soriani

Neurologist

Arnaud Declemy

Physical Medicine and Rehabilitation

Carole Barre

Study coordinator

Location

30 voie romaine, 06200,Nice,France

Contact

33492035504
Contact this centre

Current trials in this centre

Closed for participation

DAZALS

Phase 2
Industry
No

In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS.

More about this trial

Archived

PHOENIX

Phase 3
Industry
No

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035'.

More about this trial

Archived

CardinALS

Phase 2
Industry
No

The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms.

More about this trial

Archived

ADORE

Phase 3
Industry
No

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with ALS.

More about this trial

Archived

APL2-ALS-206 trial

Phase 2
Industry
No

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS.

More about this trial

Archived

COURAGE-ALS

Phase 3
Industry
No

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS.

More about this trial

Archived

ALXN1210-ALS-308 trial

Phase 3
Industry
No

This study is designed to test the efficacy and safety of intravenous Ravulizumab in patients with ALS.

More about this trial

Contact this centre

If you would like to contact us or register for a trial, leave your details here.